Laigo Bio, Utrecht-Based Biotech, Closes €17M Seed Round

The round was led by new co-lead investor Biovance Capital (€4M), alongside existing co-lead Kurma Partners (€1.5M), and is supported by Curie Capital, Argobio Studio, Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Region, and Cancer Research Horizons.

The funds will accelerate the development of Laigo’s Surface Removal Targeting Chimeras (SureTACs) oncology programs toward clinical trials and advance three candidate programs targeting autoimmune, immunology, and graft rejection indications.

Under CEO Dr. Matthew Baker, Laigo Bio is pioneering highly differentiated therapies using its proprietary SureTACs™ precision membrane protein degradation platform. Developed with Prof.

Read Also - Ex-Google Moonshot X Advisor Launches €50 Million Cloudberry Ventures DeepTech Fund

Madelon Maurice’s laboratory at UMC Utrecht and the Oncode Institute, the platform creates bispecific antibodies that link an optimal E3 ligase with a disease-causing protein, triggering its targeted ubiquitination and lysosomal degradation. This enables first-in-class, dual-targeted therapies that selectively eliminate disease-driving membrane proteins.

Dr. Matthew Baker, Chief Executive Officer of Laigo Bio, said: “The second close of our seed financing round further validates the potential of our SureTACs platform and its ability to identify first-in-class dual targeted therapies to redefine the treatment of cancer and autoimmune diseases. The additional investment and support from new co-lead investor Biovance Capital, alongside further funding from our existing co-lead investor Kurma Partners, will accelerate our oncology programs towards the clinic and enhance our discovery efforts in auto-immunity and immunology. We welcome Dr. João Incio to the Board of Directors.”

About Laigo Bio

Laigo Bio a Netherlands-based biotech, develops targeted therapies using its proprietary SureTACs™ platform. By pairing E3 ligases with disease-causing membrane proteins, it drives selective degradation, enhancing efficacy, reducing side effects, and offering deeper inhibition of autoimmune and inflammatory disease pathways compared to conventional treatments.